Display options
Cite
Bošnjak B, Odak I, Barros-Martins J, et al. Intranasal Delivery of MVA Vector Vaccine Induces Effective Pulmonary Immunity Against SARS-CoV-2 in Rodents. Front Immunol. 2021;12:772240doi: 10.3389/fimmu.2021.772240.
Bošnjak, B., Odak, I., Barros-Martins, J., Sandrock, I., Hammerschmidt, S. I., Permanyer, M., Patzer, G. E., Greorgiev, H., Gutierrez Jauregui, R., Tscherne, A., Schwarz, J. H., Kalodimou, G., Ssebyatika, G., Ciurkiewicz, M., Willenzon, S., Bubke, A., Ristenpart, J., Ritter, C., Tuchel, T., Meyer Zu Natrup, C., Shin, D. L., Clever, S., Limpinsel, L., Baumgärtner, W., Krey, T., Volz, A., Sutter, G., & Förster, R. (2021). Intranasal Delivery of MVA Vector Vaccine Induces Effective Pulmonary Immunity Against SARS-CoV-2 in Rodents. Frontiers in immunology, 12772240. https://doi.org/10.3389/fimmu.2021.772240
Bošnjak, Berislav, et al. "Intranasal Delivery of MVA Vector Vaccine Induces Effective Pulmonary Immunity Against SARS-CoV-2 in Rodents." Frontiers in immunology vol. 12 (2021): 772240. doi: https://doi.org/10.3389/fimmu.2021.772240
Bošnjak B, Odak I, Barros-Martins J, Sandrock I, Hammerschmidt SI, Permanyer M, Patzer GE, Greorgiev H, Gutierrez Jauregui R, Tscherne A, Schwarz JH, Kalodimou G, Ssebyatika G, Ciurkiewicz M, Willenzon S, Bubke A, Ristenpart J, Ritter C, Tuchel T, Meyer Zu Natrup C, Shin DL, Clever S, Limpinsel L, Baumgärtner W, Krey T, Volz A, Sutter G, Förster R. Intranasal Delivery of MVA Vector Vaccine Induces Effective Pulmonary Immunity Against SARS-CoV-2 in Rodents. Front Immunol. 2021 Nov 11;12:772240. doi: 10.3389/fimmu.2021.772240. eCollection 2021. PMID: 34858430; PMCID: PMC8632543.
Copy Download .nbib Format: NLM
Share it on

Front Immunol. 2021 Nov 11;12:772240. doi: 10.3389/fimmu.2021.772240. eCollection 2021.

Intranasal Delivery of MVA Vector Vaccine Induces Effective Pulmonary Immunity Against SARS-CoV-2 in Rodents.

Frontiers in immunology

Berislav Bošnjak, Ivan Odak, Joana Barros-Martins, Inga Sandrock, Swantje I Hammerschmidt, Marc Permanyer, Gwendolyn E Patzer, Hristo Greorgiev, Rodrigo Gutierrez Jauregui, Alina Tscherne, Jan Hendrik Schwarz, Georgia Kalodimou, George Ssebyatika, Malgorzata Ciurkiewicz, Stefanie Willenzon, Anja Bubke, Jasmin Ristenpart, Christiane Ritter, Tamara Tuchel, Christian Meyer Zu Natrup, Dai-Lun Shin, Sabrina Clever, Leonard Limpinsel, Wolfgang Baumgärtner, Thomas Krey, Asisa Volz, Gerd Sutter, Reinhold Förster

Affiliations

  1. Institute of Immunology, Hannover Medical School, Hannover, Germany.
  2. Division of Virology, Department of Veterinary Sciences, Ludwig Maximilian University (LMU) Munich, Munich, Germany.
  3. German Centre for Infection Research (DZIF), Partner Site Munich, Munich, Germany.
  4. Center of Structural and Cell Biology in Medicine, Institute of Biochemistry, University of Lübeck, Lübeck, Germany.
  5. Department of Pathology, University of Veterinary Medicine Hannover, Hannover, Germany.
  6. Institute for Virology, University of Veterinary Medicine Hannover, Hannover, Germany.
  7. German Centre for Infection Research (DZIF), Partner Site Hamburg-Lübeck-Borstel-Riems, Lübeck, Germany.
  8. Centre for Structural Systems Biology (CSSB), Hamburg, Germany.
  9. Institute of Virology, Hannover Medical School, Hannover, Germany.
  10. Cluster of Excellence RESIST (EXC 2155), Hannover Medical School, Hannover, Germany.
  11. German Centre for Infection Research (DZIF), Partner Site Hannover, Hannover, Germany.

PMID: 34858430 PMCID: PMC8632543 DOI: 10.3389/fimmu.2021.772240

Abstract

Antigen-specific tissue-resident memory T cells (Trms) and neutralizing IgA antibodies provide the most effective protection of the lungs from viral infections. To induce those essential components of lung immunity against SARS-CoV-2, we tested various immunization protocols involving intranasal delivery of a novel Modified Vaccinia virus Ankara (MVA)-SARS-2-spike vaccine candidate. We show that a single intranasal MVA-SARS-CoV-2-S application in mice strongly induced pulmonary spike-specific CD8

Copyright © 2021 Bošnjak, Odak, Barros-Martins, Sandrock, Hammerschmidt, Permanyer, Patzer, Greorgiev, Gutierrez Jauregui, Tscherne, Schwarz, Kalodimou, Ssebyatika, Ciurkiewicz, Willenzon, Bubke, Ristenpart, Ritter, Tuchel, Meyer zu Natrup, Shin, Clever, Limpinsel, Baumgärtner, Krey, Volz, Sutter and Förster.

Keywords: bronchus-associated lymphoid tissue (BALT); lungs; modified vaccinia virus Ankara (MVA); respiratory tract; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); spike (S) protein; vaccination; vaccine

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

  1. N Engl J Med. 2021 Aug 19;385(8):759-760 - PubMed
  2. Nat Commun. 2020 Aug 21;11(1):4207 - PubMed
  3. J Exp Med. 2016 Dec 12;213(13):3057-3073 - PubMed
  4. Proc Natl Acad Sci U S A. 1992 Nov 15;89(22):10847-51 - PubMed
  5. Clin Infect Dis. 2020 Dec 3;71(9):2428-2446 - PubMed
  6. Sci Rep. 2018 Jan 16;8(1):864 - PubMed
  7. J Exp Med. 2014 Apr 7;211(4):643-51 - PubMed
  8. Immunity. 2014 Dec 18;41(6):886-97 - PubMed
  9. Cell. 2021 Aug 5;184(16):4220-4236.e13 - PubMed
  10. Vaccine. 1998 Aug;16(13):1324-30 - PubMed
  11. Nature. 2020 Aug;584(7821):437-442 - PubMed
  12. Virology. 1997 Nov 24;238(2):198-211 - PubMed
  13. Science. 2020 Mar 13;367(6483):1260-1263 - PubMed
  14. J Leukoc Biol. 2014 Feb;95(2):215-24 - PubMed
  15. Viruses. 2017 May 05;9(5): - PubMed
  16. Viral Immunol. 2017 Jan/Feb;30(1):70-76 - PubMed
  17. Lancet. 2021 Jan 9;397(10269):99-111 - PubMed
  18. N Engl J Med. 2021 Jul 8;385(2):187-189 - PubMed
  19. Proc Natl Acad Sci U S A. 2021 Jul 13;118(28): - PubMed
  20. Lancet Infect Dis. 2014 Oct;14(10):939-46 - PubMed
  21. J Virol. 2013 Nov;87(21):11950-4 - PubMed
  22. Cell. 2021 Apr 29;184(9):2384-2393.e12 - PubMed
  23. Sci Immunol. 2020 Jun 11;5(48): - PubMed
  24. Methods Mol Biol. 2016;1350:349-58 - PubMed
  25. J Gen Virol. 1998 Feb;79 ( Pt 2):347-52 - PubMed
  26. J Exp Med. 2019 Dec 2;216(12):2736-2747 - PubMed
  27. Proc Natl Acad Sci U S A. 2008 Feb 12;105(6):2046-51 - PubMed
  28. Nature. 2004 Mar 11;428(6979):182-5 - PubMed
  29. Vaccines (Basel). 2020 Oct 03;8(4): - PubMed
  30. J Exp Med. 2009 Nov 23;206(12):2593-601 - PubMed
  31. Methods Mol Biol. 2017;1559:185-198 - PubMed
  32. PLoS Med. 2019 Apr 30;16(4):e1002790 - PubMed
  33. Nat Biotechnol. 2020 Sep;38(9):1073-1078 - PubMed
  34. Cell Rep. 2018 Apr 17;23(3):783-795 - PubMed
  35. J Immunol. 2003 Aug 1;171(3):1602-9 - PubMed
  36. Cell Mol Immunol. 2021 Apr;18(4):936-944 - PubMed
  37. Nature. 2020 Jul;583(7818):834-838 - PubMed
  38. J Virol. 2015 Aug;89(16):8651-6 - PubMed
  39. N Engl J Med. 2021 May 13;384(19):1866-1868 - PubMed
  40. Nat Med. 2021 May;27(5):917-924 - PubMed
  41. Sci Adv. 2021 Jul 2;7(27): - PubMed
  42. Immunity. 2021 Mar 9;54(3):542-556.e9 - PubMed
  43. Proc Natl Acad Sci U S A. 2020 Jul 14;117(28):16587-16595 - PubMed
  44. N Engl J Med. 2021 Feb 4;384(5):403-416 - PubMed
  45. Front Immunol. 2019 Mar 29;10:611 - PubMed
  46. Vaccine. 1994 Aug;12(11):1032-40 - PubMed
  47. Lancet Infect Dis. 2020 Jul;20(7):827-838 - PubMed
  48. N Engl J Med. 2004 Feb 26;350(9):896-903 - PubMed
  49. Emerg Microbes Infect. 2021 Dec;10(1):797-809 - PubMed
  50. Cell Host Microbe. 2021 Feb 10;29(2):236-249.e6 - PubMed
  51. Nucleic Acids Res. 2019 Jan 8;47(D1):D339-D343 - PubMed
  52. Cell. 2020 Oct 1;183(1):169-184.e13 - PubMed
  53. Expert Rev Vaccines. 2009 Apr;8(4):447-54 - PubMed
  54. J Immunol. 2019 Jan 15;202(2):374-381 - PubMed
  55. Sci Immunol. 2017 Jan 6;2(7): - PubMed
  56. Hum Vaccin Immunother. 2016 Apr 2;12(4):1070-9 - PubMed
  57. Nat Immunol. 2011 Dec 16;13(1):1; author reply 2 - PubMed
  58. Adv Virus Res. 2017;97:187-243 - PubMed
  59. Proc Natl Acad Sci U S A. 2004 Apr 27;101(17):6641-6 - PubMed
  60. Nat Med. 2021 May;27(5):790-792 - PubMed
  61. Nat Immunol. 2018 Feb;19(2):173-182 - PubMed
  62. Emerg Infect Dis. 2020 Jul;26(7):1478-1488 - PubMed
  63. Immunology. 1989 Jan;66(1):32-8 - PubMed
  64. Nat Commun. 2020 Nov 30;11(1):6121 - PubMed
  65. Front Immunol. 2020 Aug 07;11:1959 - PubMed
  66. Cell Mol Immunol. 2020 Feb;17(2):113-122 - PubMed
  67. Lancet Infect Dis. 2021 Dec;21(12):1654-1664 - PubMed
  68. Cell Mol Immunol. 2018 Oct;15(10):875-887 - PubMed
  69. Vaccine. 2011 Feb 11;29(8):1666-76 - PubMed
  70. Clin Microbiol Infect. 2021 Nov 23;: - PubMed
  71. Cell. 2017 Oct 5;171(2):398-413.e21 - PubMed
  72. Front Immunol. 2021 Apr 12;12:640842 - PubMed
  73. PLoS One. 2009 Sep 23;4(9):e7142 - PubMed
  74. Science. 2016 Jan 1;351(6268):77-81 - PubMed
  75. Curr Opin Immunol. 2019 Aug;59:101-108 - PubMed
  76. Lancet. 2021 Apr 10;397(10282):1351-1362 - PubMed
  77. Front Immunol. 2013 Jul 12;4:185 - PubMed
  78. Pharmaceutics. 2021 Jul 14;13(7): - PubMed
  79. Clin Vaccine Immunol. 2013 May;20(5):663-72 - PubMed
  80. N Engl J Med. 2021 May 20;384(20):1885-1898 - PubMed
  81. N Engl J Med. 2020 Dec 31;383(27):2603-2615 - PubMed
  82. Nat Med. 2021 Sep;27(9):1525-1529 - PubMed
  83. Vaccine. 2013 Sep 6;31(39):4241-6 - PubMed
  84. Vaccine. 1999 Oct 14;18(5-6):392-7 - PubMed

Publication Types